BioNTech (BNTX) Projected to Post Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect BioNTech to post earnings of $0.57 per share and revenue of $1.2054 billion for the quarter. BioNTech has set its FY 2025 guidance at EPS.Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The company had revenue of $306.46 million for the quarter, compared to analysts’ expectations of $161.26 million. During the same quarter in the prior year, the firm earned ($3.36) EPS. BioNTech’s quarterly revenue was up 102.6% compared to the same quarter last year. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Stock Performance

Shares of BNTX opened at $103.91 on Friday. The company has a 50-day simple moving average of $102.52 and a two-hundred day simple moving average of $104.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm has a market capitalization of $23.40 billion, a PE ratio of -64.94 and a beta of 1.45. BioNTech has a one year low of $81.20 and a one year high of $129.27.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Tower Research Capital LLC TRC increased its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. NewEdge Advisors LLC bought a new position in BioNTech in the 1st quarter valued at approximately $167,000. Osaic Holdings Inc. boosted its stake in BioNTech by 27.3% during the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock valued at $208,000 after purchasing an additional 418 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in BioNTech during the 2nd quarter valued at $319,000. Finally, Royal Bank of Canada increased its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after purchasing an additional 3,514 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. HC Wainwright reiterated a “buy” rating and issued a $136.00 price objective on shares of BioNTech in a report on Monday, September 8th. Bank of America dropped their target price on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Finally, Morgan Stanley dropped their price objective on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $133.96.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.